Revolutionary Drug Offers Hope For Stroke Victims
Clinical trial data show outcomes in patients with severe strokes are greatly improved following treatment with RP-1127
NEW YORK, February 6, 2013 – At the opening plenary session of the 2013 International Stroke Conference in Hawaii, some 3,000 Neurologists, Neurosurgeons, Neurointerventionalists and Nurses attending from around the world were presented with dramatic results from a drug trial in patients with severe stroke.
The study, GAMES-Pilot, was designed to test Remedy Pharmaceuticals’ novel drug, RP-1127, in patients with severe stroke who are likely to develop significant brain swelling. Based on historical data, if untreated, approximately 80% of GAMES-Pilot patients would be expected to die or survive bedridden and incontinent, requiring constant nursing care.
In stark contrast, the proportion of patients who survived without such severe disability was 90%, a reversal of the dire natural history of severe stroke. Follow up MRI images were notable for qualitative findings including absence of mass effect, and preservation of white matter.
Dr. Kevin Sheth, MD, chief, Division of Neurocritical care and Emergency Neurology, and chief of clinical research, Department of Neurology, Yale University, New Haven, Connecticut, and the Principal Investigator of the study, received the coveted Robert G. Siekert New Investigator Award in Stroke for his work on the study. “We're biased, but we believe that this is probably the most exciting treatment in acute stroke since the advent of tPA (tissue plasminogen activator)” said Dr. Sheth, continuing “We were excited because right now we have nothing to offer these patients and they often have a poor outcome, and also because the biology is very interesting and very different from what the stroke field has been doing for the last 2 decades.”
“The response by the community has been overwhelming,” says Sven Jacobson, CEO of Remedy Pharmaceuticals. “We have sites beating down our doors to be part of the follow-on study, GAMES-RP, scheduled to begin enrolling next quarter.”
Detailed information on the GAMES-Pilot Study is available at: http://clinicaltrials.gov/ct2/show/NCT01268683
Detailed information on the GAMES-RP Study is available at: http://clinicaltrials.gov/ct2/show/NCT01794182
Remedy’s lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NCCa-ATP, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.
About Remedy Pharmaceuticals
Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury. RP-1127 has not yet been approved for use by the FDA.
Contact: Sven Jacobson 212-586-2226 x 225 firstname.lastname@example.org